이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

이전에 치료받지 않은 여포성 림프종을 앓는 성인 참가자에게 화학요법과 결합된 Odronextamab의 효과와 리툭시맙 및 화학요법과 비교하여 얼마나 안전한지 알아보기 위한 연구 (OLYMPIA-2)

2026년 11월 12일 업데이트: Regeneron Pharmaceuticals

이전에 치료받지 않은 여포성 림프종 참가자를 대상으로 화학요법과 병용한 항CD20x 항CD3 이중특이성 항체인 오드로넥스타맙(REGN1979)과 화학요법과 병용한 리툭시맙의 효능 및 안전성을 비교하기 위한 제3상 공개 무작위 연구(OLYMPIA- 2)

This study is researching an experimental drug called odronextamab, referred to as study drug. The study is focused on participants with previously untreated follicular lymphoma. Follicular lymphoma is a type of non-Hodgkin lymphoma or NHL. Participants with follicular lymphoma that has come back after treatment (called "relapsed") or did not respond to treatment (called "refractory") are eligible to take part only in Part 1A of the study.

This study is made up of 3 parts: Part 1A (non-randomized), Part 1B and Part 2 (randomized - controlled).

The aim of Part 1A and Part 1B of the study is to see how safe and tolerable the study drug in combination with chemotherapy is and to determine the dose and schedule of the study drug to be combined with chemotherapy to be used in Part 2 of the study.

The aim of Part 2 of the study is to assess how effective the combination of the study drug with chemotherapy is in comparison with the combination of rituximab and chemotherapy (the current standard-of-care for NHL). Standard-of-care means the usual medication expected and used when receiving treatment for a condition.

The study is looking at several other research questions, including:

  • What side effects may happen from taking the study drug
  • How much study drug is in the blood at different times
  • Whether the body makes antibodies against the study drug (which could make the study drug less effective or could lead to side effects)
  • The impact from the study drug on quality-of-life and ability to complete routine daily activities

연구 개요

상태

모집하지 않고 적극적으로

정황

개입 / 치료

연구 유형

중재적

등록 (추정된)

733

단계

  • 3단계

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 장소

      • Kaohsiung City, 대만, 83301
        • Kaohsiung Chang Gung Memorial Hospital
      • Kaohsiung City, 대만, 80756
        • Kaohsiung Medical University Hospital
      • New Taipei City, 대만, 23561
        • Taipei Medical University - Shuang Ho Hospital
      • Taipei, 대만, 11217
        • Taipei Veterans General Hospital
      • Taipei, 대만, 11490
        • Tri-Service General Hospital
      • Taipei, 대만, 11696
        • Taipei Medical University Multipal Wan Fang University
      • Kiel, 독일, 24116
        • Stadtisches Krankenhaus Kiel
      • Neuss, 독일, 41462
        • MVZ fuer Haematologie und Onkologie Rhein-Kreis GmbH
    • Florida
      • Plantation, Florida, 미국, 33322
        • Boca Raton Clinical Research (BRCR) Global
    • Indiana
      • Noblesville, Indiana, 미국, 46062
        • Investigative Clinical Research of Indiana
    • Kansas
      • Wichita, Kansas, 미국, 67214
        • Cancer Center of Kansas
    • Kentucky
      • Lexington, Kentucky, 미국, 40536
        • University of Kentucky
    • Michigan
      • Detroit, Michigan, 미국, 48202
        • Henry Ford Health System
      • Grand Rapids, Michigan, 미국, 49503
        • Cancer and Hematology Centers of Western Michigan
    • Texas
      • Houston, Texas, 미국, 77030
        • Center for Oncology and Blood Disorders
    • Utah
      • Ogden, Utah, 미국, 84405
        • Community Cancer Trials of Utah
    • Wisconsin
      • Waukesha, Wisconsin, 미국, 53188
        • Prohealth Care Inc
      • Brussels, 벨기에, 1000
        • Institut Jules Bordet
      • Liège, 벨기에, 4000
        • Centre Hospitalier Regional de la Citadelle
    • Oost-Vlaanderen
      • Ghent, Oost-Vlaanderen, 벨기에, 9000
        • Universitair Ziekenhuis (UZ) Gent/ Ghent University Hospital
      • Sint-Niklaas, Oost-Vlaanderen, 벨기에, 9100
        • Verenigde Ziekenhuizen van Waas en Durme
    • West-Vlaanderen
      • Bruges, West-Vlaanderen, 벨기에, 8000
        • Algemeen Ziekenhuis St Jan Brugge Oostende Av
      • Kortrijk, West-Vlaanderen, 벨기에, 8500
        • AZ Groeninge
      • Rio de Janeiro, 브라질, 20231050
        • Instituto Nacional de Cancer Jose Alencar Gomes da Silva
      • São Paulo, 브라질, 01323-903
        • Hospital Alemao Oswaldo Cruz
      • São Paulo, 브라질, 08270-070
        • Casa de Saude Santa Marcelina
      • São Paulo, 브라질, 01509-010
        • AC Camargo Cancer Center
      • São Paulo, 브라질, 05403-000
        • Clinical Hospital of Medicine School at Sao Paulo University
    • Estado de Bahia
      • Salvador, Estado de Bahia, 브라질, 41253-900
        • Hospital Sao Rafael
      • Salvador, Estado de Bahia, 브라질, 41950-640
        • Ensino e Terapia de Inovacao Clinica Amo (Etica)
      • Salvador, Estado de Bahia, 브라질, 40050-410
        • Hospital Santa Izabel - Santa Casa de Misericordia da Bahia
    • Federal District
      • Brasília, Federal District, 브라질, 70200-730
        • Hospital Sirio Libanes Brasilia
      • Brasília, Federal District, 브라질, 70390-140
        • Instituto DOr de Pesquisa e Ensino Df Star
    • Minas Gerais
      • Belo Horizonte, Minas Gerais, 브라질, 30380-472
        • Instituto Mario Pena de Ensino Pesquisa e Inovacao
      • Uberlândia, Minas Gerais, 브라질, 38408-008
        • Centro Oncologico do Triangulo (COT) - Uberlandia
    • Paraná
      • Curitiba, Paraná, 브라질, 81520-060
        • Hospital Erasto Gaertner
    • Rio Grande do Norte
      • Natal, Rio Grande do Norte, 브라질, 59062-000
        • Liga Norte Riograndense Contra o Cancer
    • Rio Grande do Sul
      • Bento Gonçalves, Rio Grande do Sul, 브라질, 95700-084
        • Instituto Tacchini de Pesquisa em Saude
      • Passo Fundo, Rio Grande do Sul, 브라질, 99010-080
        • Instituto do Cancer em Hospital Sao Vicente de Paulo
      • Porto Alegre, Rio Grande do Sul, 브라질, 90035-903
        • Hospital de Clinicas de Porto Alegre
    • Santa Catarina
      • Joinville, Santa Catarina, 브라질, 89201-260
        • Centro de Hematologia e Oncologia
      • Lages, Santa Catarina, 브라질, 88501-001
        • Animi Unidade de Tratamento Oncologico Ltda
    • São Paulo
      • Barretos, São Paulo, 브라질, 14784-400
        • Fundacao Pio XII Hospital de Amor
      • Jaú, São Paulo, 브라질, 17210-080
        • Amaral Carvalho Hospital
      • Ribeirão Preto, São Paulo, 브라질, 14048-900
        • Hospital das Clinicas da Faculdade de Medicina de Ribeirao Preto
      • Lugo, 스페인, 27003
        • Hospital Universitario Lucus Augusti
      • Madrid, 스페인, 28027
        • Clinica Universidad de Navarra - Madrid
      • Madrid, 스페인, 28034
        • Hospital Universitario Ramon y Cajal
      • Madrid, 스페인, 28041
        • Hospital Universitario 12 de Octubre
      • Madrid, 스페인, 28031
        • Hospital Universitario Infanta Leonor
      • Madrid, 스페인, 28040
        • Hospital Universitario Fundacion Jimenez Diaz
      • Ourense, 스페인, 32005
        • Complexo Hospitalario Universitario de Ourense
      • Pamplona, 스페인, 31008
        • Clinica Universidad de Navarra- Pamplona
      • Salamanca, 스페인, 37007
        • Hospital Universitario de Salamanca
      • Seville, 스페인, 41009
        • Hospital Universitario Virgen Macarena
      • Valencia, 스페인, 46009
        • Instituto Valenciano de Oncologia
      • Valencia, 스페인, 46010
        • Hospital Clinico Universitario de Valencia
    • Andalusia
      • Seville, Andalusia, 스페인, 41013
        • Hospital Universitario Virgen del Rocio
    • Barcelona
      • Sabadell, Barcelona, 스페인, 08208
        • Parc Tauli Sabadell Hospital Universitari
      • Terrassa, Barcelona, 스페인, 08221
        • Hospital Universitari Mutua Terrassa
    • Bizkaia
      • Barakaldo, Bizkaia, 스페인, 48903
        • Cruces University Hospital (Hospital Universitario Cruces)
    • Madrid
      • Majadahonda, Madrid, 스페인, 28222
        • Hospital Universitario Puerta de Hierro - Majadahonda
      • Pozuelo de Alarcón, Madrid, 스페인, 28223
        • Hospital Universitario Quiron Salud Madrid
    • Navarre
      • Pamplona, Navarre, 스페인, 31008
        • Hospital Universitario de Navarra
    • Principality of Asturias
      • Oviedo, Principality of Asturias, 스페인, 33011
        • Hospital Universitario Central de Asturias
    • Valencia
      • Alicante, Valencia, 스페인, 03010
        • Hospital General Universitario Doctor Balmis Alicante
      • Aberdeen, 영국, AB25 2ZN
        • NHS Grampian: Aberdeen Royal Infirmary
    • Cornwall
      • Truro, Cornwall, 영국, TR1 3LJ
        • Royal Cornwall Hospitals NHS Trust, Royal Cornwall Hospital
    • London
      • Uxbridge, London, 영국, UB8 3NN
        • The Hillingdon Hospitals NHS Foundation Trust
    • West Midlands
      • Birmingham, West Midlands, 영국, B15 2SY
        • University Hospitals Birmingham NHS Foundation Trust
      • Vienna, 오스트리아, 1090
        • Universitatsklinik fur Kinder und Jungendheilkunde
      • Wels, 오스트리아, 4600
        • Klinikum Wels-Grieskirchen
    • Lower Austria
      • Sankt Pölten, Lower Austria, 오스트리아, 3100
        • Karl Landsteiner University Hospital St. Poelten
    • Styria
      • Graz, Styria, 오스트리아, 8036
        • Medical University of Graz
      • Leoben, Styria, 오스트리아, 8700
        • Landeskrankenhaus Hochsteiermark
    • Tyrol
      • Innsbruck, Tyrol, 오스트리아, 6020
        • Innsbruck Medical University
    • Upper Austria
      • Linz, Upper Austria, 오스트리아, 4020
        • Kepler University Hospital
      • Beersheba, 이스라엘, 84101
        • Soroka University Medical Center
      • Haifa, 이스라엘, 3109601
        • Rambam Health Care Campus
      • Jerusalem, 이스라엘, 91200
        • Hadassah Medical Center
      • Petah Tikva, 이스라엘, 49100
        • Rabin Medical Center
      • Tel Aviv, 이스라엘, 64239
        • The Tel Aviv Sourasky Medical Center
      • Tel Aviv, 이스라엘, 6971028
        • Assuta Medical Centers
    • Jerusalem
      • Jerusalem, Jerusalem, 이스라엘, 9103102
        • Shaare Zedek Medical Center
      • Milan, 이탈리아, 20141
        • Istituto Europeo di Oncologia
      • Milan, 이탈리아, 20162
        • ASST Grande Ospedale Metropolitano Niguarda - Main Address
      • Milan, 이탈리아, 20122
        • Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
      • Modena, 이탈리아, 41124
        • A.O.U. di Modena
      • Naples, 이탈리아, 80131
        • Federico II University
      • Perugia, 이탈리아, 06132
        • Azienda Ospedaliera di Perugia
      • Pisa, 이탈리아, 56126
        • University of Pisa, Section of Hematology
      • Potenza, 이탈리아, 85100
        • Azienda Ospedaliera Regionale San Carlo
      • Ravenna, 이탈리아, 48121
        • UO Ematologia Ravenna
      • Reggio Emilia, 이탈리아, 42123
        • Azienda Unita Sanitaria Locale Irccs Arcispedale Santa Maria Nuova
      • Rome, 이탈리아, 00161
        • Azienda Osperdaliero-Universitaria Policlinico Umberto 1
      • Udine, 이탈리아, 33100
        • Azienda Sanitaria Universitaria del Friuli Centrale
    • Forli-Cesena
      • Meldola, Forli-Cesena, 이탈리아, 47014
        • Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori
    • Piedmont
      • Turin, Piedmont, 이탈리아, 10137
        • Azienda Ospedaliera Ordine Mauriziano Torino, Presidio Umberto I of Turin
    • Sicily
      • Palermo, Sicily, 이탈리아, 90127
        • Azienda Ospedaliera Universitario Policlinico Palermo
    • North Central Czech Republic
      • Hradec Králové, North Central Czech Republic, 체코, 50005
        • University Hospital Hradec Kralove
    • South Moravian
      • Brno, South Moravian, 체코, 62500
        • University Hospital Brno
    • Las Condes
      • Santiago, Las Condes, 칠레, 7620157
        • Hospital Clinico Universidad de Los Andes
    • Santiago Metropolitan
      • Santiago, Santiago Metropolitan, 칠레, 7560907
        • Centro Oncologia de Precision Universidad Mayor
      • Santiago, Santiago Metropolitan, 칠레, 7580206
        • Inmunocel
      • Santiago, Santiago Metropolitan, 칠레, 7550000
        • Pontificia Universidad Catolica de Chile
      • Khon Kaen, 태국, 40002
        • Khon Kaen University
    • Krung Thep Maha Nakhon [Bangko]
      • Bangkok, Krung Thep Maha Nakhon [Bangko], 태국, 10330
        • Chulalongkorn University
      • Ankara, 터키 (Türkiye), 06100
        • Liv Hospital Ankara
      • Istanbul, 터키 (Türkiye), 34365
        • VKV American Hopital
      • Istanbul, 터키 (Türkiye), 34418
        • Istanbul University
      • Kayseri, 터키 (Türkiye), 38039
        • Erci̇yes Uni̇versi̇ty
      • Samsun, 터키 (Türkiye), 55270
        • Ondokuz Mayıs University
      • Zonguldak, 터키 (Türkiye), 67100
        • Zonguldak Bulent Ecevit University
    • Ankara
      • Mamak, Ankara, 터키 (Türkiye), 06620
        • Ankara University Faculty of Medicine
      • Yenimahalle, Ankara, 터키 (Türkiye), 06200
        • Dr. Abdurrahman Yurtaslan Oncology Training and Research Hospital
    • Central Anatolia
      • Ankara, Central Anatolia, 터키 (Türkiye), 06100
        • Gazi University
    • Mersin
      • Mezitli, Mersin, 터키 (Türkiye), 33200
        • VM Medical Park Mersin Hospital
    • Serdivan
      • Sakarya, Serdivan, 터키 (Türkiye), 54050
        • Sakarya University
    • Suleymanpasa
      • Tekirdağ, Suleymanpasa, 터키 (Türkiye), 59100
        • Tekirdag Namik Kemal University Hospital
      • Bydgoszcz, 폴란드, 85-168
        • Szpital Uniwersytecki Nr2 Bydgoszcz
      • Gdansk, 폴란드, 80-952
        • Uniwersyteckie Centrum Kliniczne, Building of the Non-Invasive Medicine Center
      • Katowice, 폴란드, 40-519
        • Pratia Onkologia Katowice
      • Lodz, 폴란드, 93-513
        • Wojewodzkie Wielospecjalistyczne Centrum Onkologii i Traumatologii im. Mikolaja Kopernika w Lodzi (Copernicus Memorial Hospital)
      • Lublin, 폴란드, 20-954
        • Centrum Innowacyjnych Terapii Samodzielny Publiczny Szpital Kliniczny Nr 4 w Lublinie
      • Warsaw, 폴란드, 02781
        • Narodowy Instytut Onkologii im Marii Sklodowskiej Curie Panstwowy Instytut Badawczy Warszawa
      • Wałbrzych, 폴란드, 58-300
        • Szpital Szpecjalistyczny w Walbrzychu
    • Lesser Poland Voivodeship
      • Krakow, Lesser Poland Voivodeship, 폴란드, 30-510
        • Matopolskie Centrum Medyczne S.C.
    • Wielkopolska
      • Skorzewo, Wielkopolska, 폴란드, 60185
        • Aidport Sp. z o.o.
      • Grenoble, 프랑스, 38043
        • Centre Hospitalier Universitaire de Grenoble
      • Le Puy-en-Velay, 프랑스, 43012
        • Centre Hospitalier Emile Roux
      • Lens, 프랑스, 62300
        • Centre Hospitalier de Lens (Centre Hospitalier Dr Schaffner dLens)
      • Paris, 프랑스, 75010
        • Hopital Saint Louis
      • Pessac, 프랑스, 33600
        • Centre Hospitalier Universitaire de Bordeaux - Groupe Hospitalier Sud - Hôpital Haut Lévêque
      • Saint-Etienne, 프랑스, 42055
        • CHU de Saint-Etienne
      • Saint-Nazaire, 프랑스, 44600
        • Centre Hospitalier de Saint Nazaire
    • Alpes Maritimes
      • Cannes, Alpes Maritimes, 프랑스, 06400
        • Cannes Hospital (Centre Hospitalier Cannes Simone Veil)
    • Centre-Val de Loire
      • Tours, Centre-Val de Loire, 프랑스, 37044
        • CHRU de Tours
    • Gard
      • Nîmes, Gard, 프랑스, 30029
        • Institut de Cancerologie du Gard
    • New Aquitaine
      • Mont-de-Marsan, New Aquitaine, 프랑스, 40024
        • Centre Hospitalier de Mont-de-Marsan
    • Pays de la Loire Region
      • Nantes, Pays de la Loire Region, 프랑스, 44093
        • Nantes University Hospital
    • Pontoise
      • Cergy-Pontoise, Pontoise, 프랑스, 95300
        • The Novo Hospital North West Val Deoise
    • Île-de-France Region
      • Argenteuil, Île-de-France Region, 프랑스, 95100
        • Hopital Victor Dupouy Argenteuil
    • New South Wales
      • Liverpool, New South Wales, 호주, 2170
        • Liverpool Hospital
      • Waratah, New South Wales, 호주, 2298
        • Calvary Mater Newcastle
    • Queensland
      • Benowa, Queensland, 호주, 4217
        • Pindara Private Hospital

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 이상 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

설명

Key Inclusion Criteria:

  1. Have diagnosis of cluster of differentiation 20 positive (CD20+) FL grade 1-3a, stage II bulky or stage III / IV

    1. For Part 1A: previously untreated participants who have Follicular Lymphoma International Prognostic Index (FLIPI)-1 score of 3 to 5, or R/R FL
    2. For Part 1B: previously untreated participants who have FLIPI-1 score of 3 to 5
    3. For Part 2: previously untreated participants who have FLIPI-1 score of 0 to 5
  2. Have measurable disease on cross sectional imaging documented by diagnostic computed tomography [CT], or magnetic resonance imaging [MRI] imaging, as described in the protocol

  3. Eastern Cooperative Oncology Group (ECOG) performance status of 0-2

  4. Adequate bone marrow and hepatic function.

Key Exclusion Criteria:

  1. Participants with central nervous system lymphoma or leptomeningeal lymphoma
  2. Participants with histological evidence of transformation to a high-grade or diffuse large B-cell lymphoma
  3. Participants with Waldenström macroglobulinemia (WM, lymphoplasmacytic lymphoma), grade 3b follicular lymphoma, chronic lymphocytic leukemia or small lymphocytic lymphoma
  4. Recent major surgery and history or organ transplantation
  5. A malignancy other than NHL unless the participant is adequately and definitively treated and any other significant active disease or medical condition that could interfere with the conduct of the study or put the participant at significant risk, as described in the protocol.

Note: Other protocol-defined Inclusion/Exclusion criteria apply

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 무작위
  • 중재 모델: 병렬 할당
  • 마스킹: 없음(오픈 라벨)

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: Odronextamab + Chemotherapy

Part 1 of the study includes ordonextamab dose escalation for participants with previously untreated FL and relapsed/refractory FL (Part 1A only) followed by a randomized exploration of 2 regimens of odronextamab (Odro) and cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) with the objective of dose optimization (Part 1B) in previously untreated patients with FL.

Administered by intravenous (IV) infusion

다른 이름들:
  • REGN1979

Administered by IV infusion

다른 이름들:
  • 사이톡산

Administered by IV infusion

다른 이름들:
  • 아드리아마이신

Administered orally (PO)

다른 이름들:
  • 델타손/옴니프레드
활성 비교기: Rituximab + Chemotherapy

In Part 2 only, participants will be randomized 1:1:1 to receive rituximab (R) with chemotherapy (CHOP), followed by rituximab monotherapy maintenance.

Administered by intravenous (IV) infusion

다른 이름들:
  • REGN1979

Administered by IV infusion

다른 이름들:
  • 사이톡산

Administered by IV infusion

다른 이름들:
  • 아드리아마이신

Administered orally (PO)

다른 이름들:
  • 델타손/옴니프레드

Administered by IV infusion, or subcutaneous (SC)

다른 이름들:
  • 리툭산

Administered by IV infusion

다른 이름들:
  • 온코빈
실험적: Odronextamab + Chemotherapy + Maintenance

In Part 2, participants will be randomized 1:1:1 to receive odronextamab with chemotherapy [CHOP, or cyclophosphamide, vincristine, and prednisone (CVP)], followed by odronextamab monotherapy maintenance.

Administered by intravenous (IV) infusion

다른 이름들:
  • REGN1979

Administered by IV infusion

다른 이름들:
  • 온코빈
실험적: Odronextamab + Chemotherapy + No maintenance

In Part 2, participants will be randomized 1:1:1 to receive odronextamab with chemotherapy (CHOP, or CVP) without maintenance.

Administered by intravenous (IV) infusion

다른 이름들:
  • REGN1979

Administered by IV infusion

다른 이름들:
  • 온코빈

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Incidence of dose limiting toxicities (DLTs) for odronextamab in combination with chemotherapy
기간: Up to 35 days

Part 1, DLT period

Up to 35 days
Incidence of treatment-emergent adverse events (TEAEs) of odronextamab in combination with chemotherapy
기간: Up to 2 years

Part 1, Treatment period

Up to 2 years
Severity of TEAEs of odronextamab in combination with chemotherapy
기간: Up to 2 years

Part 1, Treatment period

Up to 2 years
Complete Response rate at 30 months (CR30) assessed by independent central review (ICR)
기간: Up to 30 months

Part 2

Up to 30 months

2차 결과 측정

결과 측정
측정값 설명
기간
Overall Survival (OS)
기간: Up to 5 years

Part 2

Up to 5 years
CR30 as assessed by local investigator
기간: Up to 30 months

Part 2

Up to 30 months
Incidence of TEAEs
기간: Up to 2 years

Part 2

Up to 2 years
Severity of TEAEs
기간: Up to 2 years

Part 2

Up to 2 years
Change in Patient Global Impression of Severity (PGIS)
기간: Up to 5 years

Part 2 The PGIS includes a single-item to assess how a patient perceives the overall severity of cancer symptoms over the past 7 days. Patients will choose the response that best describes the severity of their overall cancer symptoms with options on a 5-point scale ranging from 1 (No symptoms) to 4 (Very Severe).

Up to 5 years
Change in Patient Global Impression of Change (PGIC)
기간: Up to 5 years

Part 2 The PGIC item includes a single-item to assess how a patient perceives their overall change in health status since the start of study treatment. Patients will choose from response options on a 7-point scale ranging from 1 (Much Better) to 7 (Much worse); 1- Much Better, 2-Moderately Better, 3-A Little Better, 4-About the Same, 5-A Little Worse, 6-Moderately Worse, 7-Much Worse.

Up to 5 years
BOR as assessed by ICR
기간: Up to 30 months

Part 2

Up to 30 months
Odronextamab concentrations in serum when administered with chemotherapy
기간: Up to 30 months

Part 1, Maintenance period and Part 2, Induction period

Up to 30 months
Odronextamab concentrations in serum when administered as monotherapy
기간: Up to 30 months

Part 1 and Part 2, Maintenance period

Up to 30 months
Incidence of anti-odronextamab antibodies (ADAs)
기간: Up to 30 months

Part 1 and Part 2

Up to 30 months
Titers of ADAs to odronextamab
기간: Up to 30 months

Part 1 and Part 2

Up to 30 months
Incidence of neutralizing antibodies (NAb) to odronextamab
기간: Up to 30 months

Part 1 and Part 2

Up to 30 months
Best overall response (BOR) as assessed by the investigator
기간: Up to 30 months

Part 1, end of Induction period and end of Maintenance period

Up to 30 months
Progression free survival (PFS) as assessed by ICR
기간: Up to 5 years

Part 2

Up to 5 years
Change in patient reported physical functioning scale scores on the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Cancer-30 (EORTC-QLQ-C30)
기간: Up to 5 years

Part 2 The EORTC QLQ-C30 includes 5 functional scales (physical, role, cognitive, emotional and social functioning), 3 symptom scales (fatigue, pain and nausea/vomiting), a global health status (GHS)/QoL scale, and six single items (constipation, diarrhea, insomnia, shortness of breath, appetite loss and financial difficulties). For the functioning scales and global health status / QoL, scores range from 1 = "very poor" to 7 = "excellent" with higher scores indicate better functioning; for the symptom scales, scores range from 1 = "not at all" to 4 = "very much" higher scores indicate higher symptom burden.

Up to 5 years
PFS as assessed by local investigator
기간: Up to 5 years

Part 2

Up to 5 years
Event-free survival (EFS) as assessed by ICR
기간: Up to 5 years

Part 2

Up to 5 years
EFS as assessed by local investigator
기간: Up to 5 years

Part 2

Up to 5 years
BOR as assessed by local investigator
기간: Up to 30 months

Part 2

Up to 30 months
Duration of response (DOR) assessed by ICR
기간: Up to 5 years

Part 2

Up to 5 years
DOR as assessed by local investigator
기간: Up to 5 years

Part 2

Up to 5 years
Time to next anti-lymphoma treatment (TTNT)
기간: Up to 5 years

Part 2

Up to 5 years
Change in patient reported health related quality of life (HRQoL) as measured by EORTC-QLQ-C30
기간: Up to 5 years

Part 2 The EORTC QLQ-C30 includes 5 functional scales (physical, role, cognitive, emotional and social functioning), 3 symptom scales (fatigue, pain and nausea/vomiting), a GHS/QoL scale, and six single items (constipation, diarrhea, insomnia, shortness of breath, appetite loss and financial difficulties). For the functioning scales and global health status / QoL, scores range from 1 = "very poor" to 7 = "excellent" with higher scores indicate better functioning; for the symptom scales, scores range from 1 = "not at all" to 4 = "very much" higher scores indicate higher symptom burden.

Up to 5 years
Change in cancer disease as measured by EORTC-QLQ-C30
기간: Up to 5 years

Part 2 The EORTC QLQ-C30 includes 5 functional scales (physical, role, cognitive, emotional and social functioning), 3 symptom scales (fatigue, pain and nausea/vomiting), a GHS/QoL scale, and six single items (constipation, diarrhea, insomnia, shortness of breath, appetite loss and financial difficulties). For the functioning scales and global health status / QoL, scores range from 1 = "very poor" to 7 = "excellent" with higher scores indicate better functioning; for the symptom scales, scores range from 1 = "not at all" to 4 = "very much" higher scores indicate higher symptom burden.

Up to 5 years
Change in treatment related symptoms as measured by EORTC-QLQ-C30
기간: Up to 5 years

Part 2 The EORTC QLQ-C30 includes 5 functional scales (physical, role, cognitive, emotional and social functioning), 3 symptom scales (fatigue, pain and nausea/vomiting), a GHS/QoL scale, and six single items (constipation, diarrhea, insomnia, shortness of breath, appetite loss and financial difficulties). For the functioning scales and global health status / QoL, scores range from 1 = "very poor" to 7 = "excellent" with higher scores indicate better functioning; for the symptom scales, scores range from 1 = "not at all" to 4 = "very much" higher scores indicate higher symptom burden.

Up to 5 years
Change in patient-reported lymphoma disease as measured by the Lymphoma Subscale of the Functional Assessment of Cancer Treatment-Lymphoma (FACT-LymS)
기간: Up to 5 years

Part 2 The FACT-Lym lymphoma subscale (LymS) includes 15 items to assess NHL-related symptoms and concerns. All questions are answered on a 5-point scale ranging from "not at all" (0) to "very much" (4). Higher scores are associated with a worse quality of life.

Up to 5 years
Change in treatment-related symptoms as measured by the FACT-LymS
기간: Up to 5 years

Part 2 The FACT-LymS includes 15 items to assess NHL-related symptoms and concerns. All questions are answered on a 5-point scale ranging from "not at all" (0) to "very much" (4). Higher scores are associated with a worse quality of life.

Up to 5 years
Change in patient-reported general health status per EuroQol-5 Dimensions-5 Levels (EQ-5D-5L)
기간: Up to 5 years

Part 2 The EQ-5D-5L consists of the EQ-5D descriptive system and the EQ visual analogue scale (EQ VAS). The EQ-5D-5L descriptive system comprises the following 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: "no problems", "slight problems", "moderate problems", "severe problems" and "extreme problems". The EQ VAS records the participant's self-rated health on a vertical visual analogue scale where the endpoints are labeled "Best imaginable health state" and "Worst imaginable health state".

Up to 5 years
Change in patient-reported treatment side effects burden per Functional Assessment of Cancer Therapy-General Global Population Item 5 (FACT-G GP5)
기간: Up to 5 years

Part 2 A single item GP5 of the validated FACT-G questionnaire will be used to assess from the participant perspective the overall impact of treatment side-effect. The question item is on a 5-point scale ranging from "not at all" (0) to "very much" (4).

Up to 5 years
Change in score of the FACT-G GP5 item in the patient population
기간: Up to 5 years

Part 2 A single item GP5 of the validated FACT-G questionnaire will be used to assess from the participant perspective the overall impact of treatment side-effect. The question item is on a 5-point scale ranging from "not at all" (0) to "very much" (4).

Up to 5 years

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

스폰서

수사관

  • 연구 책임자: Clinical Trial Management, Regeneron Pharmaceuticals

간행물 및 유용한 링크

연구에 대한 정보 입력을 담당하는 사람이 자발적으로 이러한 간행물을 제공합니다. 이것은 연구와 관련된 모든 것에 관한 것일 수 있습니다.

유용한 링크

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2023년 11월 14일

기본 완료 (추정된)

2029년 7월 29일

연구 완료 (추정된)

2029년 7월 29일

연구 등록 날짜

최초 제출

2023년 10월 18일

QC 기준을 충족하는 최초 제출

2023년 10월 18일

처음 게시됨 (실제)

2023년 10월 24일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 11월 13일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 11월 12일

마지막으로 확인됨

2026년 11월 1일

추가 정보

이 연구와 관련된 용어

기타 연구 ID 번호

  • R1979-ONC-2075
  • 2022-502113-28-00 (기타 식별자: EUCT Number)

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

예

IPD 계획 설명

All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing

IPD 공유 기간

When Regeneron has:

  • received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication or has globally discontinued development of the product for all indications on or after April 2020 and has no plans for future development
  • made the study results publicly available (e.g., scientific publication, scientific conference, clinical trial registry)
  • the legal authority to share the data, and
  • ensured the ability to protect participant privacy

IPD 공유 액세스 기준

Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf

IPD 공유 지원 정보 유형

  • 연구_프로토콜
  • 수액
  • ICF
  • ANALYTIC_CODE
  • CSR

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

예

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .